View Older Stories View More Recent Stories

Oct 3, 2022 04:50PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 3, 2022 04:50PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 7, 2022 08:00AM Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
Sep 7, 2022 08:00AM Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
Sep 1, 2022 05:27PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 1, 2022 05:27PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 15, 2022 04:57PM Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
Aug 15, 2022 04:57PM Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
Aug 10, 2022 07:00AM Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Aug 10, 2022 07:00AM Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Aug 1, 2022 04:55PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2022 04:55PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2022 08:00AM Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference
Aug 1, 2022 08:00AM Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference
Jul 5, 2022 04:01PM Cullinan Oncology to Participate in William Blair Biotech Focus Conference
Jul 5, 2022 04:01PM Cullinan Oncology to Participate in William Blair Biotech Focus Conference
Jul 1, 2022 04:37PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 1, 2022 04:37PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 23, 2022 08:00AM Cullinan Oncology (CGEM) and Taiho Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417
Jun 23, 2022 08:00AM Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417
Jun 23, 2022 08:00AM Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417
Jun 1, 2022 05:00PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 1, 2022 05:00PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2022 08:00AM Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annua
May 31, 2022 08:00AM Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annua
May 26, 2022 08:45AM Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
May 26, 2022 08:45AM Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
May 19, 2022 08:00AM Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
May 19, 2022 08:00AM Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
May 16, 2022 06:46AM Cullinan Oncology (CGEM) Reports Q1 Net Loss of $12.9M
May 16, 2022 06:45AM Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 16, 2022 06:45AM Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 12, 2022 05:50AM Cullinan Oncology (CGEM) and Taiho Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
May 12, 2022 02:00AM Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
May 12, 2022 02:00AM Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
May 2, 2022 05:00PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2022 05:00PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 27, 2022 10:00AM Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual
Apr 27, 2022 10:00AM Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual
Apr 5, 2022 08:00AM Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
Apr 5, 2022 08:00AM Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
View More Recent Stories View Older Stories